🇺🇸 FDA
Patent

US 8710026

MiR 204, miR 211, their anti-miRs, and therapeutic uses of same

granted A61KA61K31/7105A61P

Quick answer

US patent 8710026 (MiR 204, miR 211, their anti-miRs, and therapeutic uses of same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/7105, A61P, A61P27/02, A61P27/10